Clinical Characteristics of SGLT2 Inhibitor User in Type 2 Diabetes with Atherosclerotic Cardiovascular Disease or Heart Failure in a Real-World Setting

被引：0
|
作者：
Jeong, Su Jin
Park, Ie Byung
Lee, Seung Eun
Shin, Donghyun
Kim, Kyoung-Ah
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2346-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2346-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data
    Wang, Wendy
    Chen, Lin Yee
    Walker, Rob F.
    Chow, Lisa S.
    Norby, Faye L.
    Alonso, Alvaro
    Pankow, James S.
    Lutsey, Pamela L.
    [J]. MAYO CLINIC PROCEEDINGS, 2023, 98 (07) : 985 - 996
  • [2] Real-World Evidence Demonstrating The Association Of SGLT2 Inhibitors With Reduced Cardiovascular Disease In Patients With Type 2 Diabetes
    Wang, Wendy
    Chen, Lin Y.
    Walker, Rob
    Chow, Lisa
    Norby, Faye L.
    Alonso, Alvaro
    Pankow, Jim S.
    Lutsey, Pamela L.
    [J]. CIRCULATION, 2022, 145
  • [3] Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
    Lo, Shih-Chang
    Kornelius, Edy
    Liao, Pei-Lun
    Huang, Jing-Yang
    Yang, Yi-Sun
    Huang, Chien-Ning
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 200
  • [4] Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
    Nakagaito, Masaki
    Imamura, Teruhiko
    Ushijima, Ryuichi
    Nakamura, Makiko
    Kinugawa, Koichiro
    [J]. BIOMEDICINES, 2023, 11 (03)
  • [5] Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?
    Koenigsberger, Debra
    Marquez, Alexander
    Hughes, Pamela R.
    Mullen, Rebecca
    [J]. JOURNAL OF FAMILY PRACTICE, 2021, 70 (06): : E7 - E9
  • [6] Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
    Shih-Chieh Shao
    Kai-Cheng Chang
    Swu-Jane Lin
    Shang-Hung Chang
    Ming-Jui Hung
    Yuk-Ying Chan
    Edward Chia-Cheng Lai
    [J]. Cardiovascular Diabetology, 20
  • [7] Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
    Shao, Shih-Chieh
    Chang, Kai-Cheng
    Lin, Swu-Jane
    Chang, Shang-Hung
    Hung, Ming-Jui
    Chan, Yuk-Ying
    Lai, Edward Chia-Cheng
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [8] SGLT2 inhibitors and vericiguat in real-world patients admitted for worsening heart failure
    Tarantini, R.
    Acone, L.
    Alonge, S.
    Catagnano, F.
    Foti, M.
    Oldani, M.
    Mortara, A.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [9] SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
    Tarantini, R.
    Vecchi, A. L.
    Matteo, F.
    De Ponti, R.
    Mortara, A.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 779 - 779
  • [10] Real-World Study on the Effect of SGLT2 Inhibitors in Patients with Type 2 Diabetes in China
    Xue, Yaoming
    Shi, Lixin
    Yu, Xuefeng
    Wang, Yangang
    Hong, Tianpei
    Li, Xiaoying
    Ma, Jianhua
    Zhu, Dalong
    Mu, Yiming
    [J]. DIABETES, 2024, 73
12345